

Special Issue

Recent Advances in Ischemic Heart Diseases

Message from the Guest Editors

Ischemic heart disease typically leads to heart failure, which can exacerbate impaired quality of life, socioeconomic burden and is the leading cause of death worldwide. Myocardial necrosis, myocardial shock, and mechanical problems such as ventricular septal defect, papillary muscle rupture, and ventricular free wall rupture all underwrite the pathophysiology of ischemic heart failure development at the time of the myocardial infarction hospitalization. Henceforth, substantial advances are desirable to control the risk factors and search for new therapies, drug development, rapid improvement in immunotherapy technology, the emergence of new clinical trials and interventions including bypass surgery and stent placement. We kindly invite all scholars to submit original research articles and reviews on any issue pertinent to ischemic heart failure studies for this Special Issue. The theme focuses on the unique molecular and cellular roles of cardiac health management, development of novel techniques, advances in the current clinical scenario, and newly developing strategies on a variety of cardiovascular diseases.

Guest Editors

Dr. Vinay Kumar

Department of Physiology and Cell Biology, The Ohio State University
Wexner Medical Center, Columbus, OH 43210, USA

Dr. Surendra Kumar Shukla

Department of Oncology Science, OU Health Stephenson Cancer
Centre, Oklahoma City, OK 73104, USA

Deadline for manuscript submissions

closed (31 October 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



mdpi.com/si/172210

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPUS / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).